OVID · Ovid Therapeutics Inc.

This filing reports the expiration and partial exercise of the Series A Warrants issued in connection with Ovid Therapeutics’ October 2025 private placement. The warrants were unregistered securities, and their expiration triggered a final settlement event under the terms of the offering. Investors exercised the majority of the underlying rights — converting 33.597 million warrants into common stock and electing 4.883 million pre-funded warrants — both at near-identical fixed prices. The $53.9 million in gross proceeds represents new capital raised without dilution from additional debt or equity issuance beyond the warrant mechanics. While not a new financing round, this event materially increases the Company’s cash position and expands its outstanding common share count, which may affect future earnings per share calculations and voting power distribution. No exhibits are referenced in the filing, and no forward-looking guidance, management commentary, or use-of-proceeds detail beyond the gross amount is provided.